Amgen's autoimmune drug succeeds in late-stage trial

Amgen said its experimental treatment for an autoimmune disease affecting moisture-producing glands met the primary endpoint of reducing disease activity in a late-stage clinical trial. The positive pivotal-trial result improves the drug's prospects for regulatory submission and potential commercialization, though no efficacy magnitude, safety data, or approval timeline was disclosed.